KRAS variant rs61764370 is not associated with ovarian cancer risk or survival in the Ovarian Cancer Association Consortium (OCAC) or Consortium of Modifiers of BRCA1 and BRCA2 (CIMBA)

被引：0
|
作者：
Berchuck, A. [1 ]
van der Baan, F. H. [2 ]
Johnatty, S. E. [3 ]
Chenevix-Trench, G. [4 ]
Pharoah, P. D. P. [5 ]
Rookus, M. A. [2 ]
Goode, E. [6 ]
机构：
[1] Duke Univ, Med Ctr, Durham, NC USA
[2] Netherlands Canc Inst, Amsterdam, Netherlands
[3] Dept Genet, Brisbane, Qld, Australia
[4] Queensland Inst Med Res, Brisbane, Qld, Australia
[5] Univ Cambridge, Cambridge, England
[6] Mayo Clin, Rochester, MN USA
来源：
GYNECOLOGIC ONCOLOGY | 2015年 / 137卷
关键词：
D O I：
10.1016/j.ygyno.2015.01.062
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
60
引用
收藏
页码：26 / 27
页数：3
相关论文
共 50 条
  • [1] An international initiative to identify genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: the Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA)
    Georgia Chenevix-Trench
    Roger L Milne
    Antonis C Antoniou
    Fergus J Couch
    Douglas F Easton
    David E Goldgar
    Breast Cancer Research, 9
  • [2] An international initiative to identify genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers:: the Consortium of Investigators of Modifiers of BRCA1 and BRCA2(CIMBA)
    Chenevix-Trench, Georgia
    Milne, Roger L.
    Antoniou, Antonis C.
    Couch, Fergus J.
    Easton, Douglas F.
    Goldgar, David E.
    BREAST CANCER RESEARCH, 2007, 9 (02)
  • [3] Pathology of Breast and Ovarian Cancers among BRCA1 and BRCA2 Mutation Carriers: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA)
    Mavaddat, Nasim
    Barrowdale, Daniel
    Andrulis, Irene L.
    Domchek, Susan M.
    Eccles, Diana
    Nevanlinna, Heli
    Ramus, Susan J.
    Spurdle, Amanda
    Robson, Mark
    Sherman, Mark
    Mulligan, Anna Marie
    Couch, Fergus J.
    Engel, Christoph
    McGuffog, Lesley
    Healey, Sue
    Sinilnikova, Olga M.
    Southey, Melissa C.
    Terry, Mary Beth
    Goldgar, David
    O'Malley, Frances
    John, Esther M.
    Janavicius, Ramunas
    Tihomirova, Laima
    Hansen, Thomas V. O.
    Nielsen, Finn C.
    Osorio, Ana
    Stavropoulou, Alexandra
    Benitez, Javier
    Manoukian, Siranoush
    Peissel, Bernard
    Barile, Monica
    Volorio, Sara
    Pasini, Barbara
    Dolcetti, Riccardo
    Putignano, Anna Laura
    Ottini, Laura
    Radice, Paolo
    Hamann, Ute
    Rashid, Muhammad U.
    Hogervorst, Frans B.
    Kriege, Mieke
    van der Luijt, Rob B.
    Peock, Susan
    Frost, Debra
    Evans, D. Gareth
    Brewer, Carole
    Walker, Lisa
    Rogers, Mark T.
    Side, Lucy E.
    Houghton, Catherine
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2012, 21 (01) : 134 - 147
  • [4] Prevalence of the variant allele rs61764370 T>G in the 3′UTR of KRAS among Dutch BRCA1, BRCA2 and non-BRCA1/BRCA2 breast cancer families
    Antoinette Hollestelle
    Cory Pelletier
    Maartje Hooning
    Ellen Crepin
    Mieke Schutte
    Maxime Look
    J. Margriet Collee
    Anja Nieuwlaat
    Lambert C. J. Dorssers
    Caroline Seynaeve
    Yurii S. Aulchenko
    John W. M. Martens
    Ans M. W. van den Ouweland
    Joanne B. Weidhaas
    Breast Cancer Research and Treatment, 2011, 128 : 79 - 84
  • [5] Characterization of the Cancer Spectrum in Men With Germline BRCA1 and BRCA2 Pathogenic Variants Results From the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA)
    Silvestri, Valentina
    Leslie, Goska
    Barnes, Daniel R.
    JAMA ONCOLOGY, 2020, 6 (08) : 1218 - 1230
  • [6] No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer
    Hollestelle, Antoinette
    van der Baan, Frederieke H.
    Berchuck, Andrew
    Johnatty, Sharon E.
    Aben, Katja K.
    Agnarsson, Bjarni A.
    Aittomaki, Kristiina
    Alducci, Elisa
    Andrulis, Irene L.
    Anton-Culver, Hoda
    Antonenkova, Natalia N.
    Antoniou, Antonis C.
    Apicella, Carmel
    Arndt, Volker
    Arnold, Norbert
    Arun, Banu K.
    Arver, Brita
    Ashworth, Alan
    Baglietto, Laura
    Balleine, Rosemary
    Bandera, Elisa V.
    Barrowdale, Daniel
    Bean, Yukie T.
    Beckmann, Lars
    Beckmann, Matthias W.
    Benitez, Javier
    Berger, Andreas
    Berger, Raanan
    Beuselinck, Benoit
    Bisogna, Maria
    Bjorge, Line
    Blomqvist, Carl
    Bogdanova, Natalia V.
    Bojesen, Anders
    Bojesen, Stig E.
    Bolla, Manjeet K.
    Bonanni, Bernardo
    Brand, Judith S.
    Brauch, Hiltrud
    Brenner, Hermann
    Brinton, Louise
    Brooks-Wilson, Angela
    Bruinsma, Fiona
    Brunet, Joan
    Bruning, Thomas
    Budzilowska, Agnieszka
    Bunker, Clareann H.
    Burwinkel, Barbara
    Butzow, Ralf
    Buys, Saundra S.
    GYNECOLOGIC ONCOLOGY, 2016, 141 (02) : 386 - 401
  • [7] The association between Polygenic Risk Scores and contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers: Analyses in the CIMBA consortium
    Van den Broek, A.
    Robson, M. E.
    Vos, J.
    Bernstein, J. L.
    Offit, K.
    Rookus, M. A.
    Chenevix-Trench, G.
    Easton, D. F.
    Antoniou, A. C.
    Schmidt, M. K.
    EUROPEAN JOURNAL OF CANCER, 2018, 92 : S10 - S10
  • [8] Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA)
    A Osorio
    R L Milne
    G Pita
    P Peterlongo
    T Heikkinen
    J Simard
    G Chenevix-Trench
    A B Spurdle
    J Beesley
    X Chen
    S Healey
    S L Neuhausen
    Y C Ding
    F J Couch
    X Wang
    N Lindor
    S Manoukian
    M Barile
    A Viel
    L Tizzoni
    C I Szabo
    L Foretova
    M Zikan
    K Claes
    M H Greene
    P Mai
    G Rennert
    F Lejbkowicz
    O Barnett-Griness
    I L Andrulis
    H Ozcelik
    N Weerasooriya
    A-M Gerdes
    M Thomassen
    D G Cruger
    M A Caligo
    E Friedman
    B Kaufman
    Y Laitman
    S Cohen
    T Kontorovich
    R Gershoni-Baruch
    E Dagan
    H Jernström
    M S Askmalm
    B Arver
    B Malmer
    S M Domchek
    K L Nathanson
    J Brunet
    British Journal of Cancer, 2009, 101 : 2048 - 2054
  • [9] Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA)
    Osorio, A.
    Milne, R. L.
    Pita, G.
    Peterlongo, P.
    Heikkinen, T.
    Simard, J.
    Chenevix-Trench, G.
    Spurdle, A. B.
    Beesley, J.
    Chen, X.
    Healey, S.
    Neuhausen, S. L.
    Ding, Y. C.
    Couch, F. J.
    Wang, X.
    Lindor, N.
    Manoukian, S.
    Barile, M.
    Viel, A.
    Tizzoni, L.
    Szabo, C. I.
    Foretova, L.
    Zikan, M.
    Claes, K.
    Greene, M. H.
    Mai, P.
    Rennert, G.
    Lejbkowicz, F.
    Barnett-Griness, O.
    Andrulis, I. L.
    Ozcelik, H.
    Weerasooriya, N.
    Gerdes, A-M
    Thomassen, M.
    Cruger, D. G.
    Caligo, M. A.
    Friedman, E.
    Kaufman, B.
    Laitman, Y.
    Cohen, S.
    Kontorovich, T.
    Gershoni-Baruch, R.
    Dagan, E.
    Jernstrom, H.
    Askmalm, M. S.
    Arver, B.
    Malmer, B.
    Domchek, S. M.
    Nathanson, K. L.
    Brunet, J.
    BRITISH JOURNAL OF CANCER, 2009, 101 (12) : 2048 - 2054
  • [10] Prevalence of the variant allele rs61764370 T>G in the 3'UTR of KRAS among Dutch BRCA1, BRCA2 and non-BRCA1/BRCA2 breast cancer families
    Hollestelle, Antoinette
    Pelletier, Cory
    Hooning, Maartje
    Crepin, Ellen
    Schutte, Mieke
    Look, Maxime
    Collee, J. Margriet
    Nieuwlaat, Anja
    Dorssers, Lambert C. J.
    Seynaeve, Caroline
    Aulchenko, Yurii S.
    Martens, John W. M.
    van den Ouweland, Ans M. W.
    Weidhaas, Joanne B.
    BREAST CANCER RESEARCH AND TREATMENT, 2011, 128 (01) : 79 - 84
12345